Dr Helen E Bryant

Department of Oncology and Metabolism

Senior Lecturer

Head of The DNA replication and repair group

h.bryant@sheffield.ac.uk
+44 114 215 9040

Full contact details

Dr Helen E Bryant
Department of Oncology and Metabolism
GU11, G Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Qualifications

1991 - 1995  BSc  Medical Biochemistry University of Glasgow

1996 - 1999  PhD  MRC Virology Unit, Glasgow

2000 - 2003   Post-doctoral Researcher   Ludwig Institute of Cancer Research, St Mary´s Hospital, London.

2003 - 2007  Post-doctoral Researcher  YCR Institute for Cancer Studies, University of Sheffield.

2007 - 2012   RCUK Academic Fellow YCR  Institute for Cancer Studies, University of Sheffield.

2012 - 2013   Lecturer  Department of Oncology, University of Sheffield.

2013 - present  Senior Lecturer  Department of Oncology and Metabolism, University of Sheffield

Research interests

Dr Bryant has worked in the area of genome biology for 20 years. Her lab employs chemists, biologists and clinicians in order to promote a multi-disciplinary approach to translational research.

By understanding the control of the fidelity of DNA replication in normal cells we aim to understand why defects in the proteins involved are associated with cancer. Her aim is to pinpoint differences between dividing tumour cells and dividing normal cells and determine which are important in cancer development. This has enabled the group to develop drugs which can specifically kill the tumour cells rather than just all dividing cells (personalized therapy).

A separate side to Dr Bryant’s work is the development of novel transition metal-containing photodynamic therapy agents that bind to DNA and induce damage only upon irradiation with specific wavelengths of light. This is a collaboration with Prof. Julia Weinstein in the Department of Chemistry (TUOS).

To this end there are 4 board themes that overlap in the lab.

  • Understanding of the cellular pathways activated when DNA replication is perturbed.
  • Improving and understanding radiotherapy response
  • Identification of the changes in expression of these genes and phenotypic consequences in cancer
  • Exploitation of these changes in hypothesis-driven drug development.
  • Chemical development of novel therapeutic agents (focus on PDT agents)

Current projects examine these themes in Bladder, Breast, NSCLC, HNSCC and Neuroblastoma.

Publications

Journal articles

Chapters

Conference proceedings papers

  • Bradbury A, King D, Bryant H, Zenke F, Drew Y & Curtin N (2018) Investigating the effect of replication stress and other phenotypic factors as determinants of sensitivity to single agent ATR inhibitor, VE-821 in ovarian cancer cell lines. EUROPEAN JOURNAL OF CANCER, Vol. 103 (pp E32-E32) RIS download Bibtex download
  • Ritchie J, Wyld L & Bryant HE (2013) UPR Activation via glucose deprivation and depletion of GRP78 protein (using siRNA) do not alter radiosensitivity in the human breast cancer cell line MCF7. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S425-S425) RIS download Bibtex download
Research group
  • Polly Gravells - Postdoctoral Research (Biologist)
  • David King - Clinical Lecturer
  • Saskia Roetschke - Clinical Research Fellow
  • Marta Martinez - Postdoctoral Researcher (Chemist)
  • Emma Grant - Postgraduate Student
  • Callum Jones - Postgraduate Student
  • Chris Legge - Postgraduate Student
  • Thomas Jones - Postgraduate Student
  • Fatma Bucklain - Postgraduate Student
  • Hannah Gagg - Technician
Teaching interests

2012 - Postgraduate certificate in Learning and Teaching

Fellow of the Higher Education Academy

MSc - Translational Oncology

MSc - Molecular Medicine

Undergraduate - Genome Stability & Genetic Change module